Skip to main content

Table 5 Incremental analysis: Cost-utility (base case) and cost-effectiveness results

From: Cost utility of a pharmacist-led minor ailment service compared with usual pharmacist care

  Mean cost per patient (SD) Total outcome Inc. cost (AUD) Inc. outcome ICER (AUD/outcome)
Outcome = QALY
 UC $19.75 (SD $7.47) 0.0264    
 MAS $26.88 (SD $7.62) 0.0296 $7.14 0.003 $2277
Outcome = episode of appropriate pharmacist care (care meeting agreed treatment pathways)
 UC $19.75 (SD $7.47) 0.676    
 MAS $26.88 (SD $7.62) 0.866 $7.14 0.191 $37.42
Outcome = extra patient achieving symptom resolution
 UC $19.75 (SD $7.47) 0.738    
 MAS $26.88 (SD $7.62) 0.750 $7.14 0.012 $586.88
  1. AUD Australian dollars, ICER incremental cost effectiveness ratio, MAS minor ailment service, QALY quality adjusted life year, UC usual pharmacist care
  2. The costs used in the cost utility and cost effectiveness evaluations for MAS is $26.88 rather than $29.56 as a result of the decision tree modelled analysis that considers the proportion of patients in each arm receiving an outcome instead of the mean costs stated above. Similarly, UC is $19.75 instead of $22.28